Gene · 1048
CEACAM5: CEA cell adhesion molecule 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CEACAM5: CEA cell adhesion molecule 5. Genes, record 1048. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1048
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P06731 | Cell adhesion molecule CEACAM5 | 702 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents283
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026129730 A | 2026-08-12 | 1 | P06731 | Espacenet |
| EP 4725500 A2 | 2026-04-15 | 1 | P06731 | Espacenet |
| JP 2026510624 A | 2026-04-10 | 130 | P06731 | Espacenet |
| WO 2026054037 A | 2026-03-12 | 139 | P06731 | Espacenet |
| WO 2026054039 A | 2026-03-12 | 138 | P06731 | Espacenet |
| US 12565530 B2 | 2026-03-03 | 85 | P06731 | Espacenet |
| JP 2026504636 A | 2026-02-06 | 11 | P06731 | Espacenet |
| EP 4676983 A1 | 2026-01-14 | 130 | P06731 | Espacenet |
| WO 2025257185 A1 | 2025-12-18 | 21 | P06731 | Espacenet |
| WO 2025257715 A1 | 2025-12-18 | 1 | P06731 | Espacenet |
1 to 10 of 283
See all 283 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| 90Y-CT84.66 | CHEMBL2109369 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
| ARCITUMOMAB | CHEMBL2108253 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
| COL-1 | CHEMBL2109491 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
| LABETUZUMAB | CHEMBL2108501 | Carcinoembryonic antigen-related cell adhesion molecule 5 other | OTHER | ChEMBL |
| LABETUZUMAB GOVITECAN | CHEMBL3544923 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
| MEDI-565 | CHEMBL2109372 | Carcinoembryonic antigen-related cell adhesion molecule 5 cross-linking agent | CROSS-LINKING AGENT | ChEMBL |
| T84.66 | CHEMBL2109370 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
| TUSAMITAMAB RAVTANSINE | CHEMBL4298098 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
| YTTRIUM Y 90 LABETUZUMAB | CHEMBL2108818 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent | BINDING AGENT | ChEMBL |
Trials16
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05849246 | TUSAMITAMAB RAVTANSINE | PHASE2 | ClinicalTrials.gov | |
| NCT05703555 | TUSAMITAMAB RAVTANSINE | PHASE2 | ClinicalTrials.gov | |
| NCT05429762 | TUSAMITAMAB RAVTANSINE | PHASE1 | ClinicalTrials.gov | |
| NCT05245071 | TUSAMITAMAB RAVTANSINE | PHASE2 | 2025-03-25 | ClinicalTrials.gov |
| NCT05071053 | TUSAMITAMAB RAVTANSINE | PHASE2 | 2024-12-05 | ClinicalTrials.gov |
| NCT04524689 | TUSAMITAMAB RAVTANSINE | PHASE2 | 2025-03-17 | ClinicalTrials.gov |
| NCT04394624 | TUSAMITAMAB RAVTANSINE | PHASE2 | 2024-03-28 | ClinicalTrials.gov |
| NCT04154956 | TUSAMITAMAB RAVTANSINE | PHASE3 | 2024-11-01 | ClinicalTrials.gov |
| NCT02187848 | TUSAMITAMAB RAVTANSINE | PHASE1 | ClinicalTrials.gov | |
| NCT01915472 | LABETUZUMAB GOVITECAN | PHASE2 | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsNIH grants1,309
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CEACAM5 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 23 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 11 | 2025 |
| T32CA121938 | UCSD Cancer Center Training Program in Drug Development | 9 | 2025 |
| P01CA163227 | Androgen Receptor Action in Castration Resistant Prostate Cancer | 7 | 2025 |
| R01DK051362 | Regulation of Mucosal Lymphocytes | 7 | 2025 |
| P30DK034854 | Integrated Epithelial and Muscosal Biology | 6 | 2025 |
| R01CA266452 | Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage Plasticity | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 1,309Source NIH's project files
See all 1,309 nih grantsPapers3,868
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative diagnostic value of a blood-based three-gene DNA methylation assay and a seven-autoantibody panel for differentiating pulmonary nodules. | J Liq Biopsy | 2026 | 42825038 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges. | Curr Issues Mol Biol | 2026 | 42793224 | PubTator, text mining | PubMed |
| Plasma signals of lung tumor promotion and the ubiquitous challenge of biomarker specificity. | Diagnosis (Berl) | 2026 | 42757506 | PubTator, text mining | PubMed |
| Prognostic impact of CEACAM5 in nonsquamous non-small cell lung cancer: a critical reappraisal driven by cut-off optimization. | Transl Lung Cancer Res | 2026 | 42723702 | PubTator, text mining | PubMed |
| Targeted RPT of CEACAM5-Expressing Human Xenografts Using an Albumin-Binding Domain-Fused C9 Affibody: Proof-of-Principle Study. | J Nucl Med | 2026 | 42722440 | PubTator, text mining | PubMed |
| CLDN18 as a novel junctional biomarker enhancing multi-gene classification of pancreatic cancer. | Transl Oncol | 2026 | 42691511 | PubTator, text mining | PubMed |
| A Multi-Layered Proteogenomic Framework for the Prioritization of Cell Surface Therapeutic Targets: Proof-of-Concept for Metastatic Colorectal Cancer. | Cancers (Basel) | 2026 | 42649884 | PubTator, text mining | PubMed |
| CEACAM5 drives psoriatic inflammation by regulating CD8+ T cell recruitment and activation. | Biochem Biophys Rep | 2026 | 42519578 | PubTator, text mining | PubMed |
| Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder. | Oncol Res | 2026 | 42500580 | PubTator, text mining | PubMed |
| Translational Gap in Biomarker Discovery: Tumor Surface Markers Rarely Mirror Circulating Levels. | Ann Gastroenterol Surg | 2026 | 42495661 | PubTator, text mining | PubMed |
1 to 10 of 3,868
See all 3,868 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1048
GET https://conductscience.org/api/genes/v1/1048/patents?page=2